跳至主要内容
临床试验/NCT07179809
NCT07179809招募中不适用

Pilot Randomized Trial of a Virtual, Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer: Exploring Dose of Support to Optimize Adherence

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年8月21日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
1
主要终点
Safety and Adverse Events (AEs)

研究概览

简要总结

The research study is to learn how the ACLP can best support patients with stable HR+/HER2- MBC.

详细描述

Primary Objective:

Assess the feasibility of delivering the ACLP, ACLP-LC, and ACLP-LC-IHC programs in stable HR+/HER2- MBC survivors. Feasibility criteria will include the percent of eligible patients who consent to participate (feasibility is defined as 30% of those approached and are eligible end up consenting) and study retention by the last follow-up (feasibility is defined as 50% of those randomized remaining in the study and who participated in at least 75% of online sessions). Our working hypothesis is that the provision of the evidence-based, mHeath ACLP with the Learning Circle support group, with or without individual health coaching, is feasible in patients with stable HR+/HER2- MBC.

Secondary Objectives:

  1. Explore changes in targeted health behaviors of diet, exercise, and stress management.
  2. Examine changes in patient-reported outcomes (PROs), including: QOL, fatigue, sleep disturbances, mental health, social support, mindfulness, and stages of change.
  3. Examine if there are group differences in post-intervention albumin, vit D, and magnesium levels.

OUTLINE: Patients are first randomized to 1 of 3 groups.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Patients with HR+/HER2 negative MBC
  • •On first- or second-line treatment
  • •Life expectancy at least 12 months
  • •Only females
  • •Age 18 years or older
  • •Able to read, write, and speak English
  • •Willingness to follow protocol requirements
  • •Have a smartphone with access to cellular service or computer access with internet service
  • •Oriented to person, place, and time
  • •Consume less than 3 servings of fruit and vegetable/day
  • •Engage in less than 150 minutes moderate/vigorous intensity activity per week, defined as anything that causes small increases in breathing or heart rate for a sustained amount of time (e.g., brisk walking, bicycling)
  • •Engage in a mind-body practice less than 4 times a month

排除标准

  • •Another primary cancer diagnosis within past 5 years (not including non-melanoma skin cancers)
  • •Any major thought disorder (e.g., schizophrenia, dementia)
  • •Communication barriers (e.g., hard of hearing)
  • •Poorly-controlled or uncontrolled diabetes in the opinion of the physician(s)
  • •Extreme mobility issues (e.g., unable to get in and out of a chair unassisted)

研究组 & 干预措施

ACLP Program

Experimental

Participants will take part in the ACLP alone

干预措施: Demographics/Lifestyle Survey (Other)

ACLP Program + Learning Circles

Experimental

Participants will take part in the ACLP and Learning Circles

干预措施: Demographics/Lifestyle Survey (Other)

ACLP Program + Learning Circles + Individual Health Coaching

Experimental

Participants will take part in the ACLP and in Learning Circles After participants complete the ACLP with Learning Circles, they will receive up to 6 individualized health coaching sessions.

干预措施: Demographics/Lifestyle Survey (Other)

结局指标

主要结局

Safety and Adverse Events (AEs)

时间窗: Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Safety and Adverse Events (AEs)

时间窗: Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验